Department of Pharmacometrics and Molecular Modeling, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland.
Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland.
Molecules. 2022 Dec 1;27(23):8412. doi: 10.3390/molecules27238412.
Acetylsalicylic acid (ASA) is one of the first drugs to be obtained by synthesis while being the most used. It has experienced the longest lasting commercial success and is considered the most popular drug of the modern era. ASA, originally used as an anti-inflammatory medication, nowadays is predominantly used as an antiplatelet agent for prophylaxis in cardiac patients. Many studies show that the benefits of using ASA far outweigh the potential risk of side effects. With particular emphasis on the possibility of ASA repositioning for new therapies, extending the indications for use beyond the diseases from the spectrum of atherosclerotic diseases, such as cancer, requires shifting the benefit-risk ratio, although very good, even more towards safety. Interesting activities consisting not only of changing the formulation but also modifying the drug molecule seem to be an important goal of the 21st century. ASA has become a milestone in two important fields: pharmacy and medicine. For a pharmacist, ASA is a long-used drug for which individual indications are practically maintained. For a doctor, acetylsalicylic acid is primarily an antiplatelet drug that saves millions of lives of patients with coronary heart disease or after a stroke. These facts do not exempt us from improving therapeutic methods based on ASA, the main goal of which is to reduce the risk of side effects, as well as to extend effectiveness. Modified acetylsalicylic acid molecules already seem to be a promising therapeutic option.
乙酰水杨酸(ASA)是最早通过合成获得的药物之一,也是应用最广泛的药物。它经历了最长时间的商业成功,被认为是现代最受欢迎的药物。ASA 最初用作抗炎药物,如今主要用作预防心脏病患者的抗血小板药物。许多研究表明,使用 ASA 的益处远远超过潜在的副作用风险。特别强调 ASA 重新定位用于新疗法的可能性,将使用指征扩展到动脉粥样硬化疾病谱之外的疾病,如癌症,需要将受益风险比进一步向安全性倾斜,尽管已经非常好。有趣的活动不仅包括改变制剂,还包括修饰药物分子,这似乎是 21 世纪的一个重要目标。ASA 已成为两个重要领域的里程碑:药学和医学。对于药剂师来说,ASA 是一种长期使用的药物,其个体适应证实际上是保持不变的。对于医生来说,乙酰水杨酸主要是一种抗血小板药物,可挽救数百万患有冠心病或中风后的患者的生命。这些事实并不能免除我们根据 ASA 改进治疗方法,其主要目标是降低副作用风险,并延长疗效。已经有改性的乙酰水杨酸分子似乎是一种有前途的治疗选择。